<?xml version="1.0" encoding="UTF-8"?>
<p>To verify the treatment effect of LQ in vivo, the survival rate was tested at 15 days postinfection; the lung virus yield and lung inflammation (pathological state) were tested at 6 days postinfection in influenza B virus-infected mice. The results (
 <xref ref-type="fig" rid="fig4">Figure 4</xref>) showed that orally administered LQ (100–400 mg/kg/day) does not reduce IBV-induced lung viral load and mortality in mice. However, the pathological change in the lungs (
 <xref ref-type="fig" rid="fig5">Figure 5</xref>) was alleviated to a certain extent. Compared to uninfected mice (
 <xref ref-type="fig" rid="fig5">Figure 5(a)</xref>), untreated mice showed severe interstitial pneumonia at 6 days after IBV infection (
 <xref ref-type="fig" rid="fig5">Figure 5(b)</xref>). In the positive control, ribavirin treated mice (
 <xref ref-type="fig" rid="fig5">Figure 5(c)</xref>), there were a few inflammatory cells around the terminal bronchus. Although interstitial pneumonia was observed in 100–400 mg/kg/day of LQ treated mice (Figures 
 <xref ref-type="fig" rid="fig5">5(d)</xref>–
 <xref ref-type="fig" rid="fig5">5(f)</xref>), depreciation of inflammatory cells was observed in LQ treated mice lungs compared to the placebo group.
</p>
